Focal Segmental Glomerulosclerosis Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

Focal Segmental Glomerulosclerosis Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

Summary

This reports provides a data-driven overview of the current and future competitive landscape in Focal Segmental Glomerulosclerosis therapeutics.

Key Highlights

• In 2022, there will be more than 169,000 diagnosed prevalent cases of FSGS across 16 pharmaceutical markets.
• There are several marketed genericized drugs for the treatment of FSGS, which are mostly immune-suppressing in nature.
• A total of three pipeline drugs for FSGS are in Phase III globally.
• Commercial sponsors dominate clinical trial development in FSGS, with China emerging as the key countries for conducting trials in FSGS.
• Deals involving companies with FSGS assets were very scarce, with only one completed strategic alliance.
• Regulatory approval in the US for Travere Therapeutic's sparsentan for FSGS is expected in June 2023.

Scope

GlobalData’s Focal Segmental Glomerulosclerosis Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include-

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Mechanism of Action, Molecule Type and Route of Administration
• Product Profiles with Sales Forecast
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Late-to-mid-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the Focal Segmental Glomerulosclerosis market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Focal Segmental Glomerulosclerosis market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.